Cargando…

The intranasal adjuvant Endocine™ enhances both systemic and mucosal immune responses in aged mice immunized with influenza antigen

Despite availability of annual influenza vaccines, influenza causes significant morbidity and mortality in the elderly. This is at least in part a result of immunosenescence; the age-dependent decrease in immunological competence that results in greater susceptibility to infections and reduced respo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falkeborn, Tina, Hinkula, Jorma, Olliver, Marie, Lindberg, Alf, Maltais, Anna-Karin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335733/ https://www.ncbi.nlm.nih.gov/pubmed/28253901 http://dx.doi.org/10.1186/s12985-017-0698-4

Ejemplares similares

Endocine™, N3OA and N3OASq; Three Mucosal Adjuvants That Enhance the Immune Response to Nasal Influenza Vaccination
por: Falkeborn, Tina, et al.
Publicado: (2013)

RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine
por: Hayashi, Masayuki, et al.
Publicado: (2016)

Long-Lasting Mucosal and Systemic Immunity against Influenza A Virus Is Significantly Prolonged and Protective by Nasal Whole Influenza Immunization with Mucosal Adjuvant N3 and DNA-Plasmid Expressing Flagellin in Aging In- and Outbred Mice
por: Hinkula, Jorma, et al.
Publicado: (2019)

Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein
por: Sengupta, Anirban, et al.
Publicado: (2022)

Human IgM monoclonal antibodies block HIV-transmission to immune cells in cervico-vaginal tissues and across polarized epithelial cells in vitro
por: Devito, Claudia, et al.
Publicado: (2018)

DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant
por: Nyström, Sanna, et al.
Publicado: (2013)

The mucosal and systemic immune responses elicited by a chitosan‐adjuvanted intranasal influenza H5N1 vaccine
por: Svindland, Signe C., et al.
Publicado: (2011)

The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants
por: Kim, Sae-Hae, et al.
Publicado: (2017)

Mucosal Immunization and Adjuvants
por: Hasegawa, Hideki, et al.
Publicado: (2014)

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
por: Hasegawa, Hideki, et al.
Publicado: (2009)

Suitability of Polymyxin B as a Mucosal Adjuvant for Intranasal Influenza and COVID-19 Vaccines
por: Yoshino, Naoto, et al.
Publicado: (2023)

Mucosal Vaccination for Influenza Protection Enhanced by Catalytic Immune‐Adjuvant
por: Qin, Tao, et al.
Publicado: (2020)

A Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination
por: Sato-Kaneko, Fumi, et al.
Publicado: (2022)

Sex-Specific Immune Responses to Seasonal Influenza Vaccination in Diabetic Individuals: Implications for Vaccine Efficacy
por: Sengupta, Anirban, et al.
Publicado: (2023)

Potentiating Lung Mucosal Immunity Through Intranasal Vaccination
por: Nelson, Sean A., et al.
Publicado: (2021)

Nano-Encapsulated Melatonin: A Promising Mucosal Adjuvant in Intranasal Immunization against Chronic Experimental T. gondii Infection
por: Said, Doaa E., et al.
Publicado: (2022)

Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice
por: Jangra, Sonia, et al.
Publicado: (2023)

Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity
por: Hartwell, Brittany L., et al.
Publicado: (2022)

Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs
por: Dhakal, Santosh, et al.
Publicado: (2018)

Intranasal Immunization with an Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery Formulation Protects against a Respiratory Pathogen Challenge
por: Patel, Girishchandra B., et al.
Publicado: (2010)

Nano-Encapsulated Antioxidant: Retinoic Acid as a Natural Mucosal Adjuvant for Intranasal Immunization against Chronic Experimental Toxoplasmosis
por: Said, Doaa E., et al.
Publicado: (2023)

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59
por: Ren, Shu-Ting, et al.
Publicado: (2017)

Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice
por: Tada, Rui, et al.
Publicado: (2015)

Use of PELC/CpG Adjuvant for Intranasal Immunization with Recombinant Hemagglutinin to Develop H7N9 Mucosal Vaccine
por: Chen, Ting-Hsuan, et al.
Publicado: (2020)

Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
por: Ganesan, Shyamala, et al.
Publicado: (2022)

Mucosal and Systemic Immune Responses to Influenza H7N9 Antigen HA1–2 Co-Delivered Intranasally with Flagellin or Polyethyleneimine in Mice and Chickens
por: Song, Li, et al.
Publicado: (2017)

Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF‐10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses
por: Kimoto, Takashi, et al.
Publicado: (2013)

A study of Chitosan and c‐di‐GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine
por: Svindland, Signe C., et al.
Publicado: (2012)

Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice
por: Maltseva, Mariam, et al.
Publicado: (2022)

Corrigendum: Mucosal and Systemic Immune Responses to Influenza H7N9 Antigen HA1–2 Co-Delivered Intranasally With Flagellin or Polyethyleneimine in Mice and Chickens
por: Song, Li, et al.
Publicado: (2018)

Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies
por: Liu, Heng, et al.
Publicado: (2013)

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
por: Mao, Tianyang, et al.
Publicado: (2022)

Effect of mucosal adjuvant IL-1β on heterotypic immunity in a pig influenza model
por: Schmidt, Anna, et al.
Publicado: (2023)

Protective Effect against Neosporosis Induced by Intranasal Immunization with Neospora caninum Membrane Antigens Plus Carbomer-Based Adjuvant
por: Correia, Alexandra, et al.
Publicado: (2022)

Multiple nuclear-replicating viruses require the stress-induced protein ZC3H11A for efficient growth
por: Younis, Shady, et al.
Publicado: (2018)

HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV
por: Hinkula, J, et al.
Publicado: (2017)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

A multicomponent intranasal adjuvant drives durable humoral, cellular, and mucosal immune responses to SARS-CoV-2 in young and aged mice
por: Jangra, Sonia, et al.
Publicado: (2023)

Mucosal and systemic immune responses induced by intranasal immunization of recombinant Bacillus subtilis expressing the P97R1, P46 antigens of Mycoplasma hyopneumoniae
por: Wang, Yongheng, et al.
Publicado: (2019)

IL-12 plus CTB in intranasal DNA-MVA schemes improved magnitude and quality of both systemic and mucosal HIV cellular immune responses
por: Rodriguez, AM, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_uojqlpt9uepkrdkds4i6o35okg